List of Triumeq Pd drug patents
Triumeq Pd is owned by Viiv Hlthcare.
Triumeq Pd contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.
Triumeq Pd has a total of 2 drug patents out of which 0 drug patents have expired.
Triumeq Pd was authorised for market use on 30 March, 2022.
Triumeq Pd is available in tablet, for suspension;oral dosage forms.
The generics of Triumeq Pd are possible to be released after 08 December, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
| US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TRIUMEQ PD family patents
33
United States
15
Japan
13
European Union
9
Spain
7
Korea, Republic of
6
Hungary
6
Slovenia
6
Denmark
5
Portugal
5
Norway
5
Mexico
5
Hong Kong
5
Poland
4
Lithuania
4
Canada
4
Australia
3
Brazil
3
China
3
Taiwan, Province of China
3
Cyprus
3
Israel
2
Russia
2
Morocco
2
EA
2
South Africa
2
Luxembourg
2
Netherlands
1
Singapore
1
New Zealand
1
Philippines
1
Austria
1
Ukraine
1
Viet Nam
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic